AzTrials
AzTrials

Osteoarthritis, HipHAPINCT03560063

The Hip Arthroplasty Positioning Improvement Study

A study testing Corin Optimised Positioning System and Standard templating in people with Osteoarthritis, Hip and Osteoarthritis, run by University of Oxford at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The primary objective of this study is to determine whether the Corin Optimised Positioning System (Corin, U.K.) reduces the rate of hip dislocation at one-year post-operatively compared with standard templating in patients undergoing total hip replacement. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Osteoarthritis, Hip, Osteoarthritis, Arthritis
What is being tested?
Corin Optimised Positioning System and Standard templating
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
460 participants
Where
1 siteUnited Kingdom
Study dates
1 May 2018to May 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant is willing and able to give informed consent for participation in the trial
  • Diagnosed with hip OA, post-traumatic OA, inflammatory arthropathy, avascular necrosis, or congenital or developmental hip disease, avascular necrosis of the hip
  • Listed for total hip arthroplasty at one of participating centres
  • Participant is fit to undergo total hip arthroplasty based on consultant anaesthetist review
  • In the Investigator's opinion, is able and willing to comply with all trial requirements
  • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the trial
  • Female participants of child bearing potential must be willing to ensure that they use effective contraception during the trial

Who cannot join

  • Inability to provide informed consent
  • Previous surgery to the ipsilateral hip
  • Significant co-morbidities that would make follow up difficult or uncomfortable
  • Scheduled elective surgery or other procedures requiring general anaesthesia during the trial
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site, 1 recruiting
  • Nuffield Orthopaedic Centre, Oxford University Hospitals Trust

    Oxford, OX3 7LD

    Marian Montgomery, +44 1865 737262, hapi@ndorms.ox.ac.uk

    Pam Lovegrove, +44 1865 227803, pam.lovegrove@ndorms.ox.ac.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: Does the Corin Optimised Positioning System Improve Clinical Outcome in Total Hip Arthroplasty? A Multi-centre, Two-arm Randomised Control Trial

The primary objective of this study is to determine whether the Corin Optimised Positioning System (Corin, U.K.) reduces the rate of hip dislocation at one-year post-operatively compared with standard templating in patients undergoing total hip replacement.

The secondary objectives of this study are to determine whether the Corin Optimised Positioning System (Corin, U.K.) improves functional outcomes, reduces length of hospital stay, and reduces leg length discrepancy compared with standard templating in patients undergoing total hip replacement.

Read the detailed description

Osteoarthritis (OA) is the most common joint disease worldwide affecting an estimated 10% of males and 18% of females over 60 years of age. The resultant pain and loss of function can be debilitating and in developed countries represents a large socioeconomic burden, costing between 1% and 2.5% of gross domestic product, which currently stands at over £1.5 trillion. Total hip replacement (THR) is an effective treatment for end-stage hip arthritis; however, demand for the procedure is growing rapidly, fuelled by an ageing population and the obesity epidemic. In fact, rates of THR are predicted to rise 174% between 2005 and 2030. The current commissioning environment in developed countries means that investment in iterative improvements of existing THR implant designs are unlikely to yield either significant benefits to patients or be supported by health funders. The two principle issues that concern surgeons and patients are the longevity of implants and the ability of new technologies to minimise complications such as dislocation and infection. The James-Lind Priorities Setting Partnership, an internationally recognised patient-driven organisation, has recently identified these pre-operative and intra-operative factors as targets for improving outcome following hip and knee replacement.

One of the largest costs to healthcare providers following THR is dislocation. Although the dislocation rate reported in Joint Registries is between 1 and 3% we know that this significantly underestimates the true problem, as the majority of dislocation events are managed with closed reduction and do not result in revision surgery. It is estimated that dislocation is an order of magnitude more common than reported in Registry data. Literature estimates indicate a true dislocation prevalence of 3 to 15%. The cost of dislocation is significant as the problem is often recurrent, resulting in multiple hospital admissions. The resulting average cost for each patient who suffers a THR dislocation is around £30,000.

The factors that influence dislocation are poorly understood. Conventional surgical wisdom dictates that placing a cup in the Lewinneck 'safe zone' reduces both instability and wear. A recent study of 9784 primary THRs, however, demonstrated that 58% of patients who suffered a dislocation had implants judged to be in a safe position. This has led to suggestions that the idea of one generic 'safe zone' may be misleading; instead, there is a unique optimum position to place a cup in each patient undergoing THR, based on the unique and complex interaction of the spine and pelvis of the individual. Thus, in some patients, whilst the acetabular cup appears well positioned by conventional measures, pelvic tilt and spinal position mean that the cup is placed in a position of instability during some activities.

The Corin Optimised Positioning System (OPS) is a novel platform, designed to enable delivery of the prosthetic acetabular cup into an optimised position for every patient undergoing THR. It comprises two stages: pre-operative planning and intra-operative guidance. Pre-operatively, patients undergo dynamic imaging (computed tomography scanning and X-ray films). The information gained about the relative movements of a patient's spine, pelvis and hips are used to create a personalized physiological profile. This enables calculation of the optimized acetabular cup orientation for each individual. A unique physical guide (which falls under the definition of a custom-made device in the Medical Device Directive) is then created for each patient to fit precisely into the acetabular fossa, for use intra-operatively. Intra-operatively, the Corin OPS uses laser alignment to aid the surgeon in aligning the acetabular cup in the calculated optimised orientation. One laser is affixed to an immovable pelvic screw; the other is attached to the reverse of the acetabular cup. The target orientation of the cup is achieved when the two lasers are aligned.

The aim of this trial is to assess the efficacy of the use of the Corin Optimised Positioning System in reducing post-operative hip dislocation in patients undergoing total hip arthroplasty by comparing it with current standard templating in total hip arthroplasty. All total hip implants/components used in the study will be produced by Corin for uniformity and have the required approvals. There is currently no evidence that this novel approach to templating has an effect on dislocation rate. This project aims to provide evidence that this new technique can improve outcomes for patients and have the potential to reduce the need for complex, expensive revision surgery.

Being tested
Corin Optimised Positioning System, Standard templating
Keywords
arthroplasty, dislocation, templating
Medical subject headings
Osteoarthritis, Hip, Osteoarthritis, Arthritis, Musculoskeletal Diseases, Joint Dislocations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Corin Optimised Positioning SystemProcedure or surgery

    Also called K171847

    Total hip replacement with implant positioning guided by Corin Optimised Positioning System.

    The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.

  • Standard templatingProcedure or surgery

    Also called Anteroposterior and lateral hip radiographs

    Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.

Study groups in NCT03560063
Study groupRoleWhat they receive
Corin OPS armExperimentalTotal hip replacement with use of Corin Optimised Positioning System to guide implant positioning
Receives: Procedure: Corin Optimised Positioning System
Standard care armActive comparatorTotal hip replacement with standard templating to guide implant positioning
Receives: Procedure: Standard templating

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dislocation rate

    Incidence of hip dislocation within 12 months post-operatively

    Measured: 12 months

Secondary outcomes (10)
  1. Change in Harris Hip Score

    A clinician recorded outcome score to assess functional improvement.

    Measured: Measured pre-operatively (baseline) and at 3, 6 and 12 months post-operatively

  2. Change in Oxford Hip Score

    A patient reported outcome measure (PROM) to assess patient benefit

    Measured: Measured pre-operatively (baseline) and at 3, 6 and 12 months post-operatively

  3. Change in Hip and Groin Outcome Score

    A PROM to assess patient benefit

    Measured: Measured pre-operatively (baseline) and at 3, 6 and 12 months post-operatively

  4. Change in International Hip Outcome Tool 33 (iHOT33) Score

    A PROM to assess patient benefit

    Measured: Measured pre-operatively (baseline) and at 3, 6 and 12 months post-operatively

  5. Change in EuroQol 5 dimension (EQ5D) Score

    A PROM to assess patient benefit

    Measured: Measured pre-operatively (baseline) and at 3, 6 and 12 months post-operatively

  6. Change in University of California, Los Angeles (UCLA) Activity Score

    A PROM to assess patient benefit

    Measured: Measured pre-operatively (baseline) and at 3, 6 and 12 months post-operatively

  7. Change in Forgotten Joint Score

    A PROM to assess patient benefit

    Measured: Measured pre-operatively (baseline) and at 3, 6 and 12 months post-operatively

  8. Length of hospital stay

    Measurement of the length of the hospital admission for the total hip replacement. Measured in days.

    Measured: Through study completion, an average of 1 year

  9. Operation duration

    Measurement of the length of time of the total hip replacement operation. Measured in minutes.

    Measured: Through study completion, an average of 1 year

  10. Discrepancy in leg length

    Assessment for correction in discrepancy in true leg length from pre-operative to post-operative. Measured in cm

    Measured: Measured pre-operatively and at 12 months post-operatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2018
  2. Study start1 May 2018
  3. Primary completionMay 2021 (estimated)
  4. Study completionMay 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be recruited and randomised into the two parallel study arms. Interventional arm: total hip replacement with use of the Corin Optimised Positioning System to guide templating. Comparator arm: total hip replacement, guided by standard templating techniques
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
460 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03560063
Sponsor's protocol ID
IRAS 216084
Acronym
HAPI
Status last verified
May 2018
First submitted
23 May 2018
Last updated
29 Mar 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data for all primary and secondary outcome measures will be made available.

Questions about this trial

What is this clinical trial studying?

A study testing Corin Optimised Positioning System and Standard templating in people with Osteoarthritis, Hip and Osteoarthritis, run by University of Oxford at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Marian Montgomery (+44 1865 737262, hapi@ndorms.ox.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dislocation rate (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2019; AzTrials last refreshed its copy on 28 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in